CORDIS · ERYSO
Engineered erythrocytes and erythrocyte extracellular vesicles for advanced Photodynamic and Sonodynamic therapy
- Код
ERYSO- Програма
- HORIZON
- Процедура
HORIZON-MSCA-2025-SE-01-01- Статус
- SIGNED
- Период
- 01.01.2027 – 31.12.2030
Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис
Участници
| Организации | Роля | Държава | Безвъзмездна помощ |
|---|---|---|---|
| ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE | координатор | ES | 946 890 € |
| UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA | участник | IT | 340 680 € |
| FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG | участник | DE | 110 220 € |
| MAIBE SRL | участник | IT | 100 200 € |
| DANUBE PRIVATE UNIVERSITY GMBH | участник | AT | 100 200 € |
| TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY | участник | IL | 100 200 € |
| ТРАКИЙСКИ УНИВЕРСИТЕТ | участник | BG | 90 180 € |
| Prove Innomed Company Limited | асоцииран партньор | TH | |
| YAYASAN PERGURUAN TINGGI KRISTEN PETRA | асоцииран партньор | ID | |
| UNIVERSITY OF MAURITIUS | асоцииран партньор | MU | |
| UNIVERSIDAD NACIONAL DEL SUR | асоцииран партньор | AR | |
| MAHIDOL UNIVERSITY | асоцииран партньор | TH | |
| CHULALONGKORN UNIVERSITY | асоцииран партньор | TH | |
| UNIVERSIDAD DE BUENOS AIRES | асоцииран партньор | AR |
Описание
ERYSO aims to develop innovative therapeutic solutions based on photodynamic (PDT), and sonodynamic (SDT) therapies usingengineered red blood cells (RBCs) and extracellular vesicles (EVs) derived from RBCs in combination with magnetothermal (MHT)therapy. Both RBCs and RBC-derived EVs are characterized by their ability to transport hemoglobin, the body's natural oxygen carrier,and exhibit long circulation times, providing a unique advantage for therapeutic delivery. Encapsulating photosensitizers (PSs) andengineering these carriers for tumor targeting addresses a major limitation of existing PDT and SDT solutions, hypoxic tumor regions, by delivering oxygen directly to these areas, enhancing therapy efficacy. Combining PDT and SDT with MHT further amplifiestherapeutic outcomes, providing a multimodal approach to tumor eradication.Magnetic nanoparticles for MHT or titanium oxide nanoparticles for SDT will be encapsulated in the carriers to enable combination oftherapies. Tumor targeting will be achieved by functionalizing RBC glycocalyx with targeting peptides or incorporating functionalizedlipids into EVs. Enhanced tumor uptake of EVs and RBCs will be facilitated through the Focus Ultrasound (FUS) technique, whichtemporarily permeabilizes the blood-tumor barrier. Tumor targeting and oxygen delivery will be monitored using advancedmolecular imaging techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography(SPECT). Therapeutic efficacy will be evaluated in relevant tumor models, combining molecular imaging and histopathologicalanalysis.The project envisions developing personalized therapies based on autologous patient components, ensuring localized treatmentwith reduced side effects. By leveraging the natural compatibility of RBCs and EVs and integrating cutting-edge targeting and deliverytechnologies, ERYSO advances the potential of personalized and multimodal cancer therapies.
Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис · Лиценз: © European Union, CC BY 4.0 (Commission reuse policy).